SBIR Phase I: A nano-liter 3D cell culture well plate for high-throughput screening

SBIR 第一阶段：用于高通量筛选的纳升 3D 细胞培养孔板

• 批准号: 1621862
• 负责人: Deepak Solomon
• 金额: $ 22.5万
• 依托单位: Neofluidics, LLC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1621862&HistoricalAwards=false
• 关键词: SBIR; Phase; nano; liter; 3D

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project will be the development of a 3-dimensional (3D) culture well plate to be used as a high-throughput screening (HTS) tool for research and drug discovery. The core technology is a novel well plate that incorporates micron-meter-sized channels and compartments, and will have the ability to perform autonomous media exchange and drug loading non-invasively in an automated and high-speed fashion. The well plate will allow larger libraries of potential drug candidate compounds to be screened against 3D cultured cells. This would enable pharmaceutical companies and screening centers to increase the probability of finding new drug candidates by elevating the scale and throughput necessary for their discovery and validation. The technology also will increase scientific understanding of cells by providing a tool to study their behavior in an in vivo-like environment, which is important when studying tumor spheroids and exploring cancer therapeutics.This SBIR Phase I project proposes to develop a 3D cell culture tool by integrating novel microfluidic technology into a well plate format. 3D cell culture is emerging as the next generation drug screening method, as it provides a window into cellular responses by culturing and studying cells in an in vivo-like environment. Currently, however, there are no tools available in the market for testing 3D cultured cells against drug compounds in an HTS fashion. A prototype of the well plate will be fabricated and several important parameters that are required to conduct HTS studies on tumors will be studied. Parameters such as the uniformity in culturing 3D tumors, volume of media required for healthy cellular growth, and effectiveness of the plate to perform screening of drug compounds will be determined. It is anticipated that the microfluidic well plate will create a uniform number of tumors in each microfluidic well and produce results similar to those derived from the current state of the art 3D cell culture platforms. Proprietary patented microfluidic technology developed and verified during the SBIR Phase I project will help integrate 3D cell culture into the mainstream drug discovery cascade.

这个小企业创新研究（SBIR）项目的更广泛的影响/商业潜力将是开发一种三维（3D）培养孔板，用作研究和药物发现的高通量筛选（HTS）工具。 核心技术是一种新型的孔板，它包含微米级的通道和隔室，并将能够以自动化和高速的方式进行自主介质交换和药物加载。孔板将允许针对3D培养的细胞筛选更大的潜在药物候选化合物库。这将使制药公司和筛选中心能够通过提高发现和验证新药所需的规模和吞吐量来增加发现新药候选药物的可能性。该技术还将通过提供一种工具来研究细胞在类似体内环境中的行为，从而增加对细胞的科学理解，这在研究肿瘤球体和探索癌症治疗方法时非常重要。SBIR第一阶段项目提出通过将新型微流体技术集成到孔板格式中来开发3D细胞培养工具。3D细胞培养正在成为下一代药物筛选方法，因为它通过在体内样环境中培养和研究细胞提供了细胞反应的窗口。然而，目前市场上还没有工具可用于以HTS方式测试3D培养细胞对药物化合物的影响。将制作一个原型的孔板和几个重要的参数，需要进行HTS研究的肿瘤将进行研究。将确定诸如培养3D肿瘤的均匀性、健康细胞生长所需的培养基体积和板进行药物化合物筛选的有效性等参数。预期微流体孔板将在每个微流体孔中产生均匀数量的肿瘤，并产生与源自现有技术的3D细胞培养平台的结果类似的结果。在SBIR第一阶段项目期间开发和验证的专利微流控技术将有助于将3D细胞培养整合到主流药物发现级联中。